Levels of cell membrane CD59 regulate the extent of complement-mediated lysis of human melanoma cells

Laboratory Investigation

Volumn 74, Issue 1, 1996, Pages 33-42

  Brasoveanu, Lorelei Irina ^a   Altomonte, Maresa ^a   Fonsatti, Ester ^a   Colizzi, Francesca ^a   Coral, Sandra ^a   Nicotra, Maria Rita ^b   Cattarossi, Ilaria ^a   Cattelan, Alessandro ^a   Natali, Pier Giorgio ^c   Maio, Michele ^a  

^a CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^b INSTITUTE OF BIOMEDICAL TECHNOLOGIES   (Italy)

^c REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CD59 ANTIGEN;

ANTIGEN EXPRESSION; ARTICLE; CANCER CELL CULTURE; COMPLEMENT DEPENDENT CYTOTOXICITY; CORRELATION FUNCTION; CYTOLYSIS; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; MELANOMA CELL; PRIORITY JOURNAL;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD; ANTIGENS, CD46; ANTIGENS, CD55; ANTIGENS, CD59; ANTIGENS, NEOPLASM; COMPLEMENT SYSTEM PROTEINS; CYTOTOXICITY, IMMUNOLOGIC; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; GANGLIOSIDES; HUMANS; IMMUNOHISTOCHEMISTRY; MELANOMA; MEMBRANE GLYCOPROTEINS; NEVUS; PHOSPHATIDYLINOSITOL DIACYLGLYCEROL-LYASE; PHOSPHORIC DIESTER HYDROLASES; SKIN NEOPLASMS; TUMOR CELLS, CULTURED;

EID: 9044243013     PISSN: 00236837     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Bajorin DF, Chapman PB, Wong GY, Cody BV, Cordon-Cardo C, Dantes L, Templeton MA, Scheinberg D, Oettgen HF, and Houghton AN (1992). Treatment with high dose mouse monoclonal (anti-GD3) antibody R24 in patients with metastatic melanoma. Melanoma Res 2:355-362.
2. Bernhard H, Roth S, Bauerschmitz J, Meyer zum Buschenfelde K-H, and Dippold W (1992). Immunorecognition of different ganglioside epitopes on human normal and melanoma tissues. Int J Cancer 51:568-572.
3. Bjorge L, Vedeler CA, Ulvested E, and Matre R (1994). Expression and function of CD59 on colonic adenocarcinoma cells. Eur J Immunol 24:1597-1603.
4. Brasoveanu LI, Altomonte M, Gloghini A, Fonsatti E, Coral S, Gasparollo A, Montagner R, Cattarossi I, Simonelli C, Cattelan A, Attadia V, Carbone A, and Maio M (1995). Expression of protectin (CD59) in human melanoma and its functional role in cell- and complement-mediated cytotoxicity. Int J Cancer 61:548-556.
5. Breslow A (1975). Tumor thickness level of invasion and node dissection in stage-I cutaneous melanoma. Ann Surg 182: 572-575.
6. Brooimans RA, van Wieringen PAM, van Es LA, and Daha MR (1992). Relative roles of decay-accelerating factor, membrane cofactor protein, and CD59 in the protection of human endothelial cells against complement-mediated lysis. Eur J Immunol 22:3135-3140.
7. Chapman PB and Houghton AN (1991). Induction of IgG antibodies against GD3 ganglioside in rabbits by antiidiotypic monoclonal antibody. J Clin Invest 88:186-192.
8. Cheung NKV, Walter EI, Smith-Mensah WH, Ratnoff WD, Tykocinski ML, and Medof ME (1988). Decay-accelerating factor protects human tumor cells from complement-mediated cytotoxicity in vitro. J Clin Invest 81:1122-1128.
9. Clark WH, Ainsworth A, Bernardino EA, Yang CH, Mihm HC, and Reed RS (1972). The developmental biology of primary cutaneous malignant melanoma. Semin Oncol 2:83-103.
10. Davies A, Simmons DL, Hale G, Harrison RA, Tighe H, Lachmann PJ, and Waldmann H (1989). CD59, an Ly-6-like protein expressed in human lymphoid cells, regulates the action of the complement membrane attack complex on homologous cells. J Exp Med 170:637-654.
11. Davies A and Lachmann PJ (1993). Membrane defence against complement lysis: The structure and biologic properties of CD59. Immunol Res 12:258-275.
12. Dippold WG, Knuth A, and Meyer zum Buschenfelde K-H (1984). Inhibition of human melanoma cell growth in vitro by monoclonal anti-GD3-ganglioside antibody. Cancer Res 44: 806-810.
13. Dippold WG, Dienes HP, Knuth A, and Meyer zum Buschenfelde K-H (1985). Immunohistochemical localization of ganglioside GD3 in human malignant melanoma, epithelial tumors, and normal tissues. Cancer Res 45:3699-3705.
14. Fletcher A, Bryant JA, Gardner B, Judson PA, Spring FA, Parsons SF, Mallinson G, and Anstee DJ (1992). New monoclonal antibodies in CD59: Use for the analysis of peripheral blood cells from paroxysmal nocturnal haemoglobinuria (PNH) patients and for the quantitation of CD59 on normal and decay accelerating factor (DAF)-deficient erythrocytes. Immunology 75:507-512.
15. Houghton AN, Mintzer D, Cordon-Cardo C, Welt S, Fliegel B, Vadhan S, Carswell E, Melamed MR, Oettgen HF, and Old LJ (1985). Mouse monoclonal IgG3 antibody detecting GD3 ganglioside: A phase I trial in patients with malignant melanoma. Proc Natl Acad Sci USA 82:1242-1246.
16. Houghton A, Chapman P, Bajorin D, Coit D, Cordon-Cardo C, and Cheung NK (1990). Treatment of metastatic melanoma with monoclonal antibodies. Pigment Cell 10:201-213.
17. Khazaeli MB, Conry RM, and LoBuglio AF (1994). Human immune response to monoclonal antibodies. J Immunother 15:42-52.
18. Laemmli UK (1970). Cleavage of structural proteins during the assembly of the head of bacteriophage T 4. Nature (London) 227:680-685.
19. Liszewski MK, Post TW, and Atkinson JP (1989). Membrane cofactor protein (MCP or CD46): Newest member of the regulators of complement activation gene cluster. Ann Rev Immunol 9:431-455.
20. Lublin DM and Atkinson JP (1989). Decay-accelerating factor: Biochemistry, molecular biology, and function. Ann Rev Immunol 7:35-58.
21. Maio M, Altomonte M, Tatake R, Zeff RA, and Ferrone S (1991). Reduction in susceptibility to natural killer cell-mediated lysis of human F 0-1 melanoma cells after induction of HLA class I antigen expression by transfection with B2 m gene. J Clin Invest 88:282-289.
22. Meri S, Morgan BP, Davies A, Daniels RH, Olavesen MG, Waldmann H, and Lachmann PJ (1990). Human protectin (CD59), an 18,000-20,000 MW complement lysis restricting factor, inhibits C5b-8 catalysed insertion of C9 into lipid bilayers. Immunology 71:1-9.
23. Meri S, Waidmann H, and Lachmann PJ (1991). Distribution of protectin (CD59), a complement membrane attack inhibitor, in normal human tissues. Lab Invest 65:532-536.
24. Mittelman A, Chen ZJ, Kageshita T, Yang H, Yamada M, Baskind P, Goldberg N, Puccio C, Ahmed T, Arlin Z, and Ferrone S (1990). Active specific immunotherapy in patients with melanoma. J Clin Invest 86:2136-2144.
25. Mittelman A, Chen ZJ, Yang H, Wong GY, and Ferrone S (1992). Human high molecular weight melanoma-associated antigen (HMW-MAA) mimicry by mouse anti-idiotypic monoclonal antibody MK 2-23: Induction of humoral anti-HMW-MAA immunity and prolongation of survival in patients with stage IV melanoma. Proc Natl Acad Sci USA 89:466-470.
26. Morgan BP and Meri S (1994). Membrane proteins that protect against complement lysis. Springer Semin Immunopathol 15:369-396.
27. Ollert MW, Kadlec JV, David K, Petrella EC, Bredehorst R, and Vogel C-W (1994). Antibody-mediated complement activation on nucleated cells. J Immunol 153:2213-2221.
28. Rooney IA and Morgan BP (1990). Protection of human amniotic epithelial cells (HAEC) from complement-mediated lysis: Expression on the cells of three complement inhibitory membrane proteins. Immunology 71:308-311.
29. Rooney IA and Morgan BP (1992). Characterization of the membrane attack complex inhibitory protein CD59 antigen on human amniotic cells and in amniotic fluid. Immunology 76:541-547.
30. Rooney IA, Atkinson JP, Krul ES, Schonfeld G, Polakoski K, Saffitz JE, and Morgan BP (1993). Physiologic relevance of the membrane attack complex inhibitory protein CD59 in human seminal plasma: CD59 is present on extracellular organelles (prostasomes), binds cell membranes, and inhibits complement-mediated lysis. J Exp Med 177:1409-1420.
31. Stefanova I, Hilgert I, Kristofova H, Brown R, Low MG, and Horejsi V (1989). Characterization of a broadly expressed human leucocyte surface antigen MeM- 43 anchored in membrane through phosphatidylinositol. Mol Immunol 26: 153-161.
32. Tandon N, Yan SL, Morgan BP, and Weetman AP (1994). Expression and function of multiple regulators of complement activation in autoimmune thyroid disease. Immunology 81:643-647.
33. Temponi M, Romano G, D'Urso CM, Wang Z, Kekish U, and Ferrone S (1989). Purification of murine IgG monoclonal antibodies by precipitation with caprylic acid: Comparison with other methods of purification. Hybridoma 8:85-95.
34. Thurin J, Thurin M, Kimoto Y, Herlyn M, Lubeck MD, Elder DE, Smereczynska M, Karlsson K-A, Clark WM, Jr., Steplewski Z, and Koprowski H (1987). Monoclonal antibody-defined correlations in melanoma between levels of GD2 and GD3 antigens and antibody-mediated cytotoxicity. Cancer Res 47:1229-1233.
35. Tsuchida T, Saxton RE, Morton DL, and Irie RF (1989). Gangliosides of human melanoma. Cancer 63:1166-1174.
36. Vadhan-Raj S, Cordon-Cardo C, Carswell E, Mintzer D, Dantis L, Duteau C, Templeton MA, Oettgen HF, Old LJ, and Houghton AN. Phase I trial of a mouse monoclonal antibody against GD (1988)3 ganglioside in patients with melanoma: Induction of inflammatory responses at tumor sites. J Clin Oncol 6:1636-1648.